AI Article Synopsis

  • Ceftaroline fosamil is FDA-approved for treating acute bacterial skin infections and community-acquired pneumonia, but its real-world usage and safety profiles in veterans are not well understood.
  • A study conducted in 69 VHA hospitals analyzed data from 764 predominantly male patients (97%) with an average age of 61, highlighting a range of infections treated with ceftaroline, including skin (40%) and sepsis (30%).
  • Results showed a low all-cause in-hospital mortality rate (5%), aligning closely with clinical trial findings, indicating that ceftaroline is effectively managing infections with minimal adverse effects among veterans.

Article Abstract

Background: Ceftaroline fosamil is US Food and Drug Administration-approved for acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia, but it is not known how ceftaroline is being used in real-world settings or how adverse effects (AEs) and mortality compare to clinical trials.

Objective: This study describes ceftaroline use, AEs, and mortality in US Veterans Health Administration (VHA) hospital patients.

Methods: This phase IV, population-based, epidemiologic study analyzed patients ≥18 years old who received one or more ceftaroline doses within 14 days of admission to 69 VHA hospitals in 41 US states/territories from 1 October 2010 to 30 September 2014. VHA repository data were linked using unique patient identifiers. Diagnoses and AEs were determined using ICD9-CM and CSS codes. Demographics, AEs within 30 days of therapy initiation, and all-cause in-hospital mortality were summarized using descriptive statistics.

Results: 764 Patients met study criteria. Patients were 97% male and 56% White, with a median age of 61 years and a Charlson score of 6. Diagnoses included skin (40%), sepsis (30%), osteomyelitis (25%), diabetic foot (22%), pneumonia (16%), bacteremia (11%), endocarditis (6%), meningitis (2%), and device (2%) infections. Ceftaroline was used first-line (37%), second-line (56%), and third-line or greater (7%). Patients received ceftaroline a median of 3 days after hospital admission. All-cause in-hospital mortality rates were: overall (5%), skin (2%), sepsis (9%), osteomyelitis (3%), diabetic foot (1%), pneumonia (13%), bacteremia (6%), endocarditis (11%), meningitis (6%), and device (13%). Eosinophilia, leukopenia, leukocytosis, fibromyalgia, myalgia and myositis, and polymyalgia rates were <1% each.

Conclusions: Ceftaroline is used in VHA hospitals for various diagnoses. Mortality was low and comparable with rates from clinical trials. Additional studies comparing ceftaroline to other drugs used in similar situations are needed.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5553123PMC
http://dx.doi.org/10.1007/s40265-017-0785-2DOI Listing

Publication Analysis

Top Keywords

ceftaroline fosamil
8
veterans health
8
aes mortality
8
received ceftaroline
8
all-cause in-hospital
8
in-hospital mortality
8
diabetic foot
8
meningitis device
8
ceftaroline
6
early ceftaroline
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!